Just posted on the other topical finasteride thread ill repeat it here :-
Remember there was also that somewhat pointless Phase lll from Admirall earlier this year testing their liposomal Finasteride this is actually set to seek approval in Q4 of this year, if that was the case it would have to wait around 2 months for it to be approved so we could be looking at a new form of topical finasteride available( my source is hairlosscure 2020 though so I suppose a grain of salt should be pinched) . We are still non the wiser about its side effects though as Serum T and DHT were never tested.... but we may at least have something we can trial ourselves by next year.
Hairloss cure 2020:-
"
Update: June 6, 2019
It seems like P-3074 will be called ALM12845 when finally released. Per Almirall’s first quarter 2019 filings:
“The top-line Phase III results for ALM12845 (androgenic alopecia) in the EU show statistical significance for the primary end-point (Change of Target Area Hair Count) at week 24. We expect the submission in Europe of ALM12845 in Q4 2019.”
My guess is that a “submission” in Europe means the same as in the US: i.e., the company is filing for approval to sell the new drug after successful Phase 3 trial completion."
Remember there was also that somewhat pointless Phase lll from Admirall earlier this year testing their liposomal Finasteride this is actually set to seek approval in Q4 of this year, if that was the case it would have to wait around 2 months for it to be approved so we could be looking at a new form of topical finasteride available( my source is hairlosscure 2020 though so I suppose a grain of salt should be pinched) . We are still non the wiser about its side effects though as Serum T and DHT were never tested.... but we may at least have something we can trial ourselves by next year.
Hairloss cure 2020:-
"
Update: June 6, 2019
It seems like P-3074 will be called ALM12845 when finally released. Per Almirall’s first quarter 2019 filings:
“The top-line Phase III results for ALM12845 (androgenic alopecia) in the EU show statistical significance for the primary end-point (Change of Target Area Hair Count) at week 24. We expect the submission in Europe of ALM12845 in Q4 2019.”
My guess is that a “submission” in Europe means the same as in the US: i.e., the company is filing for approval to sell the new drug after successful Phase 3 trial completion."